Elmiron Lawsuit

Elmiron® (pentosan polysulfate sodium) is the subject of recent lawsuits that highlight the drug’s connection to numerous vision problems. Victims of eye damage related to this drug may be eligible to file an Elmiron lawsuit to pursue financial compensation. Contact the Elmiron lawyers at Sokolove Law to get a free legal case review.

Breaking News: Drug Label Now Warns of Vision Harm

In June 2020, Elmiron maker Janssen Pharmaceuticals updated the drug’s product labeling to warn of vision problems.

The label now states Elmiron can change pigments in the retina, causing blurred vision, reading problems, and sensitivity to low light. It also recommends that all who use Elmiron should have their eyesight regularly tested.

While this warning may be helpful information for future Elmiron users, it comes too late for those already suffering from eye damage.

Further, the label states that a patient's eyesight can continue to worsen even if they stop using Elmiron. These changes may not be reversible.

Elmiron Lawsuits: IC Drug Linked to Eye Problems

Elmiron, a prescription drug used to treat bladder pain and discomfort associated with interstitial cystitis (IC), has come under fire for its link to serious eye damage. Elmiron users across the United States claim that the drug may cause many vision issues.

Elmiron lawsuits allege that the company did not disclose the link between Elmiron use and serious vision damage.

If you or a loved one take or have taken Elmiron and suffered an eye disorder or vision issues as a result, you may have a case.

Recent Elmiron Lawsuit

On May 4, 2020, a Nevada woman filed a complaint against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, alleging that their product (Elmiron) caused her to develop the retinal disease maculopathy.

The Nevada woman faced chronic exposure to Elmiron, having used the drug since 2012. Her personal injury lawsuit states that her vision began to deteriorate after taking the medication for six years.

What Is Elmiron Used For?

Approved by the U.S. Food and Drug Administration (FDA) in 1996, pentosan polysulfate sodium (Elmiron) is the only FDA-approved oral medication used to treat bladder pain and discomfort associated with interstitial cystitis (IC).

IC, also known as “painful bladder syndrome,” is a chronic bladder condition with no known cure.

Elmiron Side Effects

Recent studies have investigated the link between the use of Elmiron and eye damage.

Elmiron may be linked to the following diseases:

  • Macular degeneration
  • Pigmentary maculopathy
  • Retinal maculopathy

Other Elmiron side effects may include:

  • Blurred vision
  • Difficulty reading
  • Distorted vision
  • Eye pain
  • Issues adjusting to darkness
  • Vision disturbances
  • Vision loss

If you or a loved one used this IC drug and have since developed one of the vision impairments listed above, you may be eligible to file an Elmiron lawsuit.

For more information, contact Sokolove Law today. Our team of Elmiron attorneys and Case Managers are available 24/7 to answer your questions and provide support.

Frequently Asked Questions About Elmiron

Below we have listed answers to some of the most common questions patients ask about Elmiron.

Does Elmiron cure interstitial cystitis?

Elmiron is not a cure for interstitial cystitis (IC). Currently, palliative treatments may lessen or relieve some of the symptoms associated with bladder pain syndrome, but medications alone will not eliminate the disorder.

Often, an IC patient may need to undergo several different therapies before identifying a combination that provides noticeable relief. For roughly half of all IC patients, symptoms may eventually go away naturally.

How long should you take Elmiron?

For an IC patient who begins an Elmiron regimen, it may take between 3 and 6 months of continuous treatment before noticeable signs of relief.

After the first 3 months, a patient should be reassessed by their doctor. Depending on the effectiveness of the drug and the absence of side effects, a doctor may then recommend extending Elmiron therapy another 3 to 6 months.

Some Elmiron patients continue using the drug for up to 15 to 20 years or more.

Can Elmiron cause blindness?

In several recent studies, clinical researchers have identified a link between the use of Elmiron and macular degeneration, a condition that over time can lead to permanent vision loss.

In a 2019 study, 91 Elmiron patients who had taken the drug for more than 15 years were tested for vision problems. Of the 91 patients, 22 had clear indications of retinal damage associated with macular degeneration.

Is there a substitute for Elmiron?

Elmiron is currently the only FDA-approved drug for the treatment of IC.

While there are no other approved medications for this condition, many doctors treat patients with a combination of other methods, which may include diet modification and pain relievers like ibuprofen.

Work With a Dangerous Drugs Law Firm — Sokolove Law

Elmiron lawsuits allege that the drug maker did not disclose the link between Elmiron use and serious vision damage and failed to warn patients about this risk.

Given that Elmiron sales amount to at least $150 Million per year and is the only IC prescription on the market, countless Americans may be at risk of developing a serious eye condition.

Get a Free Legal Case Review

You may be entitled to compensation if you’ve developed vision problems after taking Elmiron. Contact Sokolove Law today for a free legal case review and to learn more about your options.

Free Case Review

Note: Do not change medications without first consulting your doctor.
All brands are trademarks of their respective companies.

Author:Sokolove Law Team
Sokolove Law Team

Contributing Authors

The Sokolove Law Content Team is made up of writers, editors, and journalists. We work with case managers and attorneys to keep site information up to date and accurate. Our site has a wealth of resources available for victims of wrongdoing and their families.

Last modified: September 10, 2020

View 2 Sources
  1. Nezgoda, J. T., & Jain, N. (2018, December 7). Pigmentary Maculopathy From Chronic Exposure to Pentosan Polysulfate Sodium. Retrieved from https://www.aao.org/interview/pigmentary-maculopathy-from-chronic-exposure-to-pe
  2. Kimberly Pelczar v. Teva Branded Pharmaceutical Products R&D, et al., 3:20-cv-00406 (Conn 2020).